Key result
Cautious TGF-β inhibition may benefit heart failure patients with overactive fibrosis but requires mechanism-driven classification.
Why the study?
Understanding cell-specific actions of TGF-β is necessary to design therapeutic strategies targeting myocardial fibrosis and remodeling in patients with heart failure.
This review highlights the complex, cell-specific roles of TGF-β in myocardial fibrosis and heart failure, suggesting that targeted TGF-β inhibition could be a therapeutic strategy for specific patient subsets.
Answers are grounded in this paper and cite their sources.
Requires mechanism-driven selection for TGF-β therapies in HF; extends fibrosis research toward precision trials.
INTRODUCTION: Myocardial fibrosis accompanies most cardiac conditions and can be reparative or maladaptive. Transforming Growth Factor (TGF)-β is a potent fibrogenic mediator, involved in repair, remodeling, and fibrosis of the injured heart. AREAS COVERED: This review manuscript discusses the role of TGF-β in heart failure focusing on cellular mechanisms and therapeutic implications. TGF-β is activated in infarcted, remodeling and failing hearts. In addition to its fibrogenic actions, TGF-β has a broad range of effects on cardiomyocytes, immune, and vascular cells that may have both protective and detrimental consequences. TGF-β-mediated effects on macrophages promote anti-inflammatory transition, whereas actions on fibroblasts mediate reparative scar formation and effects on pericytes are involved in maturation of infarct neovessels. On the other hand, TGF-β actions on cardiomyocytes promote adverse remodeling, and prolonged activation of TGF-β signaling in fibroblasts stimulates progression of fibrosis and heart failure. EXPERT OPINION: Understanding of the cell-specific actions of TGF-β is necessary to design therapeutic strategies in patients with myocardial disease. Moreover, to implement therapeutic interventions in the heterogeneous population of heart failure patients, mechanism-driven classification of both HFrEF and HFpEF patients is needed. Heart failure patients with prolonged or overactive fibrogenic TGF-β responses may benefit from cautious TGF-β inhibition.
No takes yet. Share an insight, caveat, or question.
Nikolaos G. Frangogiannis (2024) conducted a review in Heart failure and myocardial infarction. TGF-β inhibition was evaluated. Cautious TGF-β inhibition may benefit heart failure patients with prolonged or overactive fibrogenic responses, though its pleiotropic effects require mechanism-driven patient classification.
Synapse has enriched 10 related papers. Consider them for comparative context: